科前生物
(688526)
| 流通市值：71.74亿 | | | 总市值：71.74亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 665,506,663.22 | 400,510,475.63 | 204,929,240.4 | 1,064,074,588.89 |
| 营业收入 | 665,506,663.22 | 400,510,475.63 | 204,929,240.4 | 1,064,074,588.89 |
| 二、营业总成本 | 393,227,605.15 | 241,479,146.09 | 117,548,562.59 | 547,826,665.17 |
| 营业成本 | 239,543,620.7 | 147,241,803.17 | 68,367,813.67 | 296,946,582.34 |
| 税金及附加 | 4,425,630.06 | 2,639,821.27 | 1,316,779.35 | 6,840,333.87 |
| 销售费用 | 93,026,235.06 | 56,108,072.46 | 31,848,987.78 | 154,836,459.09 |
| 管理费用 | 41,088,599.54 | 25,394,130.7 | 11,186,340.52 | 67,044,235.14 |
| 研发费用 | 61,152,604.48 | 40,359,385.44 | 19,840,800.13 | 88,505,343.58 |
| 财务费用 | -46,009,084.69 | -30,264,066.95 | -15,012,158.86 | -66,346,288.85 |
| 其中:利息费用 | 4,553,324.05 | 3,345,757.16 | 2,005,025.73 | 8,158,805.33 |
| 其中:利息收入 | 50,740,386.7 | 33,776,797.01 | 17,029,790.46 | 74,587,150.96 |
| 加:公允价值变动收益 | 17,180,358.45 | 6,442,306.81 | 878,049.98 | -10,194,774.37 |
| 加:投资收益 | 11,262,998.83 | 3,688,044.98 | 2,893,431.31 | 19,532,528.49 |
| 资产处置收益 | 926,906.06 | 926,906.06 | 926,906.06 | - |
| 资产减值损失(新) | -17,299,862.03 | -9,697,299.89 | -2,903,421.2 | -15,793,212.07 |
| 信用减值损失(新) | -7,057,566.43 | -3,466,812.06 | -478,018.34 | -80,370,379.52 |
| 其他收益 | 20,216,362.37 | 16,671,873.89 | 11,927,047.88 | 29,709,604.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 297,508,255.32 | 173,596,349.33 | 100,624,673.5 | 459,131,690.91 |
| 加:营业外收入 | 93,582.98 | 3,434.5 | 3,434.02 | 134,324.35 |
| 减:营业外支出 | 790,205.91 | 669,951.73 | 618,536.98 | 1,685,350.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 296,811,632.39 | 172,929,832.1 | 100,009,570.54 | 457,580,664.5 |
| 减:所得税费用 | 36,804,185.17 | 20,693,684 | 12,933,889.88 | 62,000,111.8 |
| 六、净利润 | 260,007,447.22 | 152,236,148.1 | 87,075,680.66 | 395,580,552.7 |
| 持续经营净利润 | 260,007,447.22 | 152,236,148.1 | 87,075,680.66 | 395,580,552.7 |
| 归属于母公司股东的净利润 | 260,600,917.75 | 152,608,566.88 | 87,228,395.78 | 395,934,947.68 |
| 少数股东损益 | -593,470.53 | -372,418.78 | -152,715.12 | -354,394.98 |
| (一)基本每股收益 | 0.56 | 0.33 | 0.18 | 0.85 |
| (二)稀释每股收益 | 0.56 | 0.33 | 0.18 | 0.85 |
| 八、其他综合收益 | -7,555,091.9 | 4,375,869.32 | 3,322,297.47 | 25,333,622.92 |
| 归属于母公司股东的其他综合收益 | -7,555,091.9 | 4,375,869.32 | 3,322,297.47 | 25,333,622.92 |
| 九、综合收益总额 | 252,452,355.32 | 156,612,017.42 | 90,397,978.13 | 420,914,175.62 |
| 归属于母公司股东的综合收益总额 | 253,045,825.85 | 156,984,436.2 | 90,550,693.25 | 421,268,570.6 |
| 归属于少数股东的综合收益总额 | -593,470.53 | -372,418.78 | -152,715.12 | -354,394.98 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-02 |
| 审计意见(境内) | | | | 标准无保留意见 |